Company intelligence / Profile preview

Mapmyhealth

Ownership: Private
Development stage: Commercial

Overview

Mapmyhealth delivers digital therapeutics embedded into standard care pathways, with its flagship product Mapmydiabetes being the only NICE-endorsed software-based support program for type 2 diabetes. The company reports use by over 70,000 patients in the UK and demonstrates clinical value through both trial and real-world data[1][2].

Therapeutic areas: PulmonologyEndocrinologyOncologyDermatology
Modalities: Non-pharmacological therapyDevice (digital therapeutic platform/software)
Industry: Digital Health Medical Devices

Drug pipeline

4 assets

Mapmydiabetes

Commercial

Indications: Type 2 diabetes

3 more assets in the full pipeline.

Request access →

Partnerships

NHS practices and healthcare providers in the UK

Beyond the preview

Go deeper on Mapmyhealth.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mapmyhealth.

Explore the full profile